An interventional study of CPETecho in Dyspnea; Cardiac, sponsored by Ziekenhuis Oost-Limburg. Recruiting at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by Ziekenhuis Oost-Limburg · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Dyspnea with a site in Belgium — 3 open to participants now, 3 under way, none of them phase 3. Dyspnea · Belgium.
Among the 19 studies in Dyspnea with a site in Belgium, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 18th registered.
895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.
Browse Dyspnea studies →3 of the 19 studies in Dyspnea with a site in Belgium are open now. Recruiting first, the newest first:
Pfizer · Sites in Belgium, United States, Argentina and 12 more countries
Ages 18–75
KU Leuven · Sites in Belgium
Ages 18+ · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 4
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 50 across 588 interventional studies indexed under Dyspnea.
Median enrollment 120 across the 13 interventional studies, 1,387 across the 6 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
Ziekenhuis Oost-Limburg is the lead sponsor of 69 studies on the registry; 16 are open to participants now.
Ziekenhuis Oost-Limburg has 1 study filed under Dyspnea — fewer than ten, so there is no comparison to draw.
1 of the studies in Dyspnea with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Dyspnea with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
CPETecho is progressively employed in diagnostic settings for pathophysiological detection, offering comprehensive assessment of both pulmonary and cardiac functions. This technique evolves from its invasive counterpart, where a diagnostic catheter is employed for hemodynamic monitoring, by substituting the invasive component with non-invasive echocardiography. Nevertheless, data on the test-retest reliability of CPETecho remain sparse, a factor critical in differentiating between measurement effects and actual therapeutic impacts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Unstable symptoms, whereby therapy cannot be delayed for a week.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Repeat CPET echo with a one-week interval
Diagnostic Test: CPETecho
repeat CPETecho with a one-week interval
Correlation coefficient (ICC)
Analysing the Test-Retest Reliability of Cardiopulmonary Exercise Testing with Echocardiography
Time frame: Up to 2 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2026, 4 months after the start.
Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 4 months is below that.
Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ziekenhuis Oost-Limburg